For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
Goodfellow Gems #156
Wednesday 15 September 2021, 12:10 AM

“Time to switch from ACE inhibitors to ARBs – same efficacy but safer”
A head-to-head comparison trial of angiotensin II receptor blockers versus ACE inhibitors exhibited no difference in outcomes except for fewer drug wi
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.
References
1. mayocl.in/2WniHF5 (Mayo Clin Proc 2016;91[1]:51– 60).
2. bit.ly/3yeMVa8 (Hypertension 2021;78[3]:591–603).